What Does "Microdosing" Mean — and Why Doesn't the Term Fit Amanita Muscaria?

"Microdosing" means repeatedly taking a small fraction of a dose of a classic psychedelic, such as psilocybin or LSD, that is meant to produce no obvious intoxication. The term was built around those drugs and their research. It does not transfer cleanly to Amanita muscaria, which works on a different brain system and has no standardised dose at all.

Where Did the Word "Microdosing" Come From?

The modern idea of microdosing grew out of the psychedelic community in the 2010s. People described taking tiny amounts of LSD or psilocybin mushrooms every few days while going about normal life. The claims were broad: better mood, sharper focus, more creativity.

Researchers soon noticed that the word itself had no agreed meaning. A 2019 review in the Journal of Psychopharmacology by Kuypers and colleagues stated plainly that there was "no agreed scientific consensus on what microdosing is" (Kuypers et al., 2019). The authors also warned that research should look at possible risks of repeated low doses, not only the reported benefits.

The same year, Polito and Stevenson published one of the first systematic observational studies of people who microdose psychedelics (Polito & Stevenson, PLoS ONE, 2019). They found that participants expected large, wide-ranging benefits, while the changes they actually reported were much narrower. That gap between expectation and outcome is a theme that runs through the whole field.

What Does a Microdose Actually Have to Be?

Most working definitions share three parts. Each part assumes things about the substance that are only known for well-studied drugs.

• A known reference dose. A microdose is defined as a fraction of a "full" dose. That only works if the full dose is measurable and consistent from one batch to the next.
• A sub-perceptual effect. The amount is supposed to be too low to notice. This assumes the dose-response curve is smooth and predictable.
• A repeated schedule. Doses are taken regularly over weeks. This assumes the substance does not build up, and that repeated exposure is reasonably safe.

For psilocybin and LSD, researchers can at least measure the active compound and study repeated exposure under controlled conditions. That is why placebo-controlled microdosing trials now exist for those drugs. None of these three assumptions has been established for Amanita muscaria.

Why Doesn't Psychedelic Dose Vocabulary Transfer to Amanita?

The first reason is pharmacology. Psilocybin and LSD act mainly on serotonin 5-HT2A receptors. Amanita muscaria's main active compounds, ibotenic acid and muscimol, act on glutamate and GABA-A receptors instead (Michelot & Melendez-Howell, Mycological Research, 2003). Different receptors mean different effects, different risks and a different relationship between amount and response. Borrowing the word "microdose" quietly borrows safety assumptions that belong to another drug class.

The second reason is chemistry. Ibotenic acid converts to muscimol as the mushroom dries, and the balance between the two shifts with handling and storage (Tsunoda et al., Journal of the Food Hygienic Society of Japan, 1993). Levels also vary between individual mushrooms. So there is no fixed "full dose" to take a fraction of. We explain this measurement problem in more depth in our article on why weight in grams is the wrong unit for Amanita.

The third reason is regulation. In September 2024 the US Food and Drug Administration concluded that Amanita muscaria, its extracts and its active constituents do not meet the criteria for general recognition of safety in food, and that there is inadequate data showing their consumption is safe (FDA Scientific Memorandum, 2024). A word that sounds precise and gentle does not change that assessment.

What Evidence Exists for Amanita "Microdosing" Specifically?

Very little. There are no controlled trials of repeated low-level Amanita muscaria use. The most cited document is a single retrospective case description posted as a preprint, based on one person's own account (Turkia, PsyArXiv preprint, 2023). A single self-reported case cannot separate the substance from expectation, time or other life changes.

By contrast, the documented record on the risk side is growing. A 2025 Lithuanian case series described four people hospitalised after intentional use, with tremors, dizziness, paranoia and, in some cases, respiratory failure (Savickaitė & Laubner-Sakalauskienė, Acta Medica Lituanica, 2025). A fatality case series was published in 2022 (Meisel et al., Wilderness & Environmental Medicine, 2022). For a wider look at how this vocabulary is misused, see why "microdosing" means something different for Amanita than for psilocybin.

What Should You Make of "Well-Being" Claims?

Well-being is a real and measurable outcome. But it rises and falls on its own, and it is very sensitive to what people expect. Even for psilocybin and LSD, a self-blinding study of 191 people found that the placebo group improved as much as the microdose group, with no significant difference between them (Szigeti et al., eLife, 2021). That context matters when reading any claim about Amanita, which has never been tested this way. For the differences between the two mushrooms, our comparison of Amanita muscaria and psilocybin mushrooms is a useful starting point.

If you are looking for better well-being, the approaches with the strongest evidence are ordinary ones: regular sleep, physical activity, social contact and, where needed, professional support from a doctor or therapist.

Frequently Asked Questions

What does microdosing mean?

It usually means repeatedly taking a small fraction of a psychedelic dose, such as psilocybin or LSD, intended to cause no obvious intoxication. Researchers note there is still no agreed scientific definition.

Is Amanita muscaria a psychedelic like psilocybin?

No. Psilocybin acts mainly on serotonin receptors. Amanita muscaria's compounds, ibotenic acid and muscimol, act on glutamate and GABA-A receptors, so its effects and risks are different.

Is there a standard microdose of Amanita muscaria?

No. Active compound levels vary between mushrooms and change with drying and storage, so there is no reliable reference dose to take a fraction of.

Has Amanita microdosing been studied in clinical trials?

No controlled trials exist. The most cited account is a single retrospective case description, which cannot show whether the substance caused any change.

Is Amanita muscaria considered safe to eat?

No. In 2024 the FDA concluded it does not meet the criteria for general recognition of safety in food, and case reports document serious poisonings.

Disclaimer: This article is educational and is not medical advice. Amanita muscaria is toxic, and Amanita Store does not sell it for human consumption. If you or someone else has symptoms after eating any wild mushroom, contact a doctor, your local poison control centre or emergency services straight away.